With over 15 years of experience in the Romanian pharmaceutical market, Elena Barbu joins MAYOLY as Country Lead in Romania, effective October 19, 2026. Her commercial expertise, in-depth knowledge of the sector and proven experience in developing strategic partnerships will be valuable assets in supporting the subsidiary’s growth.
This appointment reflects MAYOLY’s development ambitions in Central and Eastern Europe (CEE), where Romania is a strategic market for the Group. It demonstrates MAYOLY’s commitment to driving growth by leveraging strong local market knowledge, engaged leadership and long-term partnerships.
Welcome to MAYOLY, Elena, and best wishes for success in your new role !
2025 Sustainability Report
Driven by our purpose, “improving the health and well-being of all to offer everyone a better everyday life,” our CSR approach actively contributes to our ambition to become a global leader in consumer healthcare.
Explore our Sustainability Report to discover our commitments, achievements and ambitions for a more sustainable future.
At Mayoly, we remain committed to supporting the climate transition through greenhouse gas emissions reduction targets validated by the Science Based Targets initiative (SBTi).
By 2030, we are committed to reducing our direct emissions (Scopes 1 and 2) by 50% compared with 2019, and our indirect emissions (Scope 3) by 55% per million euros of value added.
We are already making tangible progress. Thanks to our increased use of renewable electricity and the gradual electrification of our sites, we have reduced our Scope 1 and 2 emissions by 41% in fiscal year 2025, compared with 2019.
At the same time, our emissions remained stable in 2025 despite the continued growth of our business, demonstrating our ability to combine business growth with environmental responsibility.
Our next challenge is to accelerate emissions reductions across our value chain, including purchasing, transportation and other upstream and downstream activities. To achieve this, we are already working closely with our partners to develop increasingly sustainable solutions.
TOPICREM reaches a new milestone in its scientific commitment with the publication of its first study in the Journal of Cosmetic Dermatology (JCD), a leading international journal in dermo-cosmetics.
This publication highlights the results of a clinical study conducted on two flagship products: the Relipidizing Cleansing Oil and the DA PROTECT Emollient Balm, developed to meet the specific needs of atopic-prone skin.
Clinically proven results
The study underscores the benefits of daily use of these products, including:
· strengthening of the skin barrier
· improvement in hydration and comfort
· a significant contribution to quality of life and emotional well-being in patients with atopic dermatitis
These results confirm TOPICREM’s expertise in developing skincare that combines dermatological performance with sensorial appeal.
A commitment to patients
This publication reflects TOPICREM’s determination to rely on robust scientific data to support patients in their daily lives. It also demonstrates the teams’ dedication to designing innovative formulas aimed at sustainably improving the comfort of sensitive and atopic skin.
👉 View the full study: HERE
Sustainability Report 2024
Our CSR approach is supported by our purpose, “improving health and well-being for everyone to offer a better daily life for each individual,” and contributes to our ambition of becoming a global leader in public health.
Mayoly is reaching an important milestone in its commitment to the energy transition and the fight against climate change. We are proud to announce that our near-term decarbonization trajectory, aimed at limiting global warming to 1.5°C by 2030, has been validated by the Science Based Targets initiative (SBTi).
This validation confirms our desire to combine economic growth and environmental responsibility and reflects on the need for decisive action to limit the global temperature increase and call on all our stakeholders to take similar steps.
By significantly reducing our greenhouse gas (GHG) emissions, we are actively participating in the global effort to combat global warming.
An ambitious trajectory by 2030, Mayoly is committed to:
- Reduce our GHG emissions from scopes 1 and 2 by 50% (direct and indirect emissions linked to the energy used)
- Reduce our emissions linked to the supply chain (scope 3) by 55% per million euros of added value
The climate emergency pushes us to act now. Every action counts for a greener future. These priorities transform the way we operate, from resource management to the way we produce, distribute our products and manage our vehicle fleet.
Review of our actions in 2024
- A strengthened eco-responsible approach: 100% renewable electricity and a responsible purchasing charter
As part of our commitment, we have taken several immediate and concrete measures. Since January 2024, all our industrial sites have been powered by 100% renewable electricity (ENR), an important step in optimizing our energy consumption and reducing our carbon footprint as a preamble to our energy sobriety plan and decarbonization roadmap developed this year.At the same time, we have implemented a responsible purchasing policy in 2024. More than 50% of our suppliers have already signed this charter, allowing us to guarantee that our supply chain meets the highest environmental and social standards. This approach reinforces our commitment to a more sustainable future at every stage of our operations.
- Why is a carbon footprint essential for a company?
A carbon footprint is a key tool for understanding a company’s impact on the climate. It measures the GHG emissions generated by the company, whether direct or indirect. To achieve effective decarbonization objectives, it is essential to know precisely where these emissions come from. This assessment helps us to set clear objectives, such as those validated by the SBTi, and to adjust our actions accordingly.
- Why it is urgent to act?
Climate change is a global and urgent challenge. Each company must take its share of responsibility to limit its impact. By reducing its GHG emissions and pollution across its entire value chain, a companynot only contributes to the fight against global warming and the preservation of the environment and the health of all living things, but it also meets the growing expectations of stakeholders – customers, investors, and regulators. For MAYOLY, acting now as a responsible player means being ready to seize the opportunities of a market that is increasingly focused on sustainability.
- An inspiring model for the sector
With this validation, MAYOLY joins a global movement of decarbonization in the pharmaceutical industry. Our trajectory validated by the SBTi is a model of strong commitment, illustrating our desire to play a leading role in the ecological transition of our sector. At MAYOLY, we are convinced that every action counts. Our commitment to decarbonization will contribute to building a more environmentally sustainable future.
- Our 2023 carbon footprint
Under the SBTi initiative, total reported emissions are 80,008 tonnes of CO2 for 2019 and 82,014 tonnes of CO2 for 2023 respectively.
Scopes 1 and 2 emissions: down -18% in 2023 compared with 2019 (7985 TCO2eq. in 2023 vs. 9761 TCO2eq. in 2019), in line with our trajectory.
Scope 3 emissions per million euros of added value: -5% in 2023 vs. 2019.
As for our ambition to reduce our scope 3 emissions associated with the purchase of goods and services, the transport and distribution of our products, business and personal travel, waste and the end-of-life of products, we are at the very beginning of the journey.
Announcement – Executive Vice President & Chief Financial Officer
Sophie DESLOGES has an extensive experience in all areas of the finance role. She has held key roles at Forvia, Wabtec/Faiveley, GE Power Conversion and Deloitte.
Sophie holds a degree from the Paris Superior Business School (ESCP) and is a certified public accountant. She is currently deepening her knowledge with an Executive Master’s in “Change and Sustainability” at HEC Paris.
Her track record and numerous successes in her previous companies in all aspects of financial performance will be major assets in supporting the Group’s development and accelerating MAYOLY’s performance
SAVE THE DATE : Mayoly Gastro Days 2024
Mayoly Gastro Days 2024: Your connection to the latest advancements and insights in hepato-gastroenterology!
Connect on December 13-14 as we team up with 11 leading European experts to discuss pivotal advances in hepato-gastroenterology.
Expect engaging discussions, valuable expert insights, and shared practices to elevate your expertise in gastroenterology.
Be informed of the full program and REGISTER for this special event here
Sustainability Report 2023
Our CSR approach is supported by our purpose, “improving health and well-being for everyone to offer a better daily life for each individual,” and contributes to our ambition of becoming a global leader in public health.
We are thrilled to welcome Adam Zarnowski as our new General Manager for Poland and Central Eastern Europe (CEE).
With over 30 years of experience in the healthcare industry, Adam brings a wealth of expertise and leadership. He has successfully led commercial activities across the CEE region, driving significant growth and innovation.
His extensive experience in both commercial and academic settings, combined with a PhD from the Medical University of Warsaw, equips him to expand MAYOLY in this key region.
